latest news stock values companies glp-1 obesity cardiometabolic The rate in the US fell in 2023 as GLP-1s go mainstream Betting on GLP-1 - by

In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]

Solutions like healthcare digital engagement platforms allow practices to track patient progress and intervene earlier when needed

MEN2) Cancer history (personal + family) GI/pancreatitis & gallbladder history Mental health conditions multi-select Diabetes (insulin / non-insulin / prediabetes) Primary care provider continuity check USPSTF-style lifestyle trial (150 min/wk for 6 months) Ros intake does not use a validated PHQ-2 or PHQ-9 depression screen depression is only a checkbox in a larger mental-health list

Fewer Overdoses and Drug-Related Deaths The study also examined outcomes among the 81,617 participants who already had a substance use disorder